Novartis already markets the PI3Kα inhibitor Piqray for breast cancer, but acquiring a Synnovation Therapeutics subsidiary brings an early clinical program that the pharma company claims could be best in the class of next-generation therapies for the target. Competitors include Eli Lilly, Relay Therapeutics, and OnKure Therapeutics.
The post Why Novartis Is Paying $2B for a Cancer Drug That Hits the Same Target as One of Its Own Products appeared first on MedCity News.
